The product model S-DTB-2601-PG corresponds to the S-(-) enantiomer of 2,6-diamino-4,5,6,7-tetrahydrobenzothiazole, systematically named (6S)-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine. The substance is supplied as the pharma grade free base and is specified for use in oral tablets, capsules, granules, and injectable preparations. Molecular formula C₇H₁₁N₃S; relative molecular mass 169.25 g/mol; monoisotopic mass 169.0674 Da. The chiral centre at the 6-position is controlled by enantioselective synthesis and chiral HPLC release testing; the material is not a racemate and is not interchangeable with technical-grade 2,6-diamino-4,5,6,7-tetrahydrobenzothiazole without chiral qualification.

The free base is a white to almost white crystalline powder. It is slightly soluble in neutral water and readily soluble in dilute mineral acids through protonation of the two amine centres. Bulk storage is maintained at 2–8°C in double polyethylene liners inside a foil laminate outer bag containing desiccant. The API is not supplied as a sterile powder; injectable manufacture therefore includes aseptic filtration or terminal sterilization after dissolution. For oral solid dosage use, the material is released with a defined particle size range to reduce segregation and content uniformity risk. The principal solid-state degradation routes are oxidative attack on the thiazole sulfur and, at elevated temperature and moisture, hydrolytic ring-opening. Protection from light, oxygen, and humidity above 60% RH is therefore required during dispensing and formulation.

What Distinguishes the S-(-) Free Base from Racemic or Technical-Grade 2,6-Diamino-4,5,6,7-tetrahydrobenzothiazole?

The S-(-) pharma grade free base differs from racemic and technical-grade material in chiral purity, organic impurity profile, elemental impurity control, residual solvent control, and microbiological release status. Racemic material contains approximately 48–52% of the R-(+) enantiomer. If the R enantiomer is present in a chiral API candidate, it is treated as a chiral impurity with separate pharmacological and toxicological qualification requirements. Release testing by chiral HPLC on an amylose tris(3,5-dimethylphenylcarbamate) stationary phase separates the enantiomers; the acceptance limit for the R enantiomer is ≤ 0.5%. Detection is performed at 265 nm with peak-purity confirmation for the S-(-) peak.

Chemical purity differences are equally significant for formulation performance. Technical-grade material may contain transition-metal residues such as palladium or platinum, high-boiling solvents, and unspecified organic impurities above 1.0%. The pharma grade API is released against ICH Q3D elemental impurity limits and ICH Q3C residual solvent limits. When used in parenteral products, an additional risk assessment is applied for elemental impurities because permitted daily exposure values are lower by injection. The technical-grade product is not released for microbial or endotoxin content and is unsuitable for tablet, capsule, granule, or injectable manufacturing without full rework and qualification.

Direct compression and dry granulation routes require the S-(-) free base to be pre-blended with a filler that does not generate reducing-sugar adducts. Lactose monohydrate is generally avoided in wet granulation because the primary amine can participate in Maillard-type condensation under elevated temperature and moisture. Mannitol, microcrystalline cellulose, and dibasic calcium phosphate dihydrate are preferred fillers. In a high-shear granulator, the dry mixture is granulated with an aqueous binder solution of povidone K30 at 3–5% w/w of dry mass. Impeller tip speed is maintained between 3 m/s and 8 m/s, and granulation endpoint is determined by impeller torque and near-infrared moisture rather than fixed time. The wet mass is dried in a fluid-bed dryer at inlet air 60–70°C to a final loss on drying of 0.5–1.0%. For tablets, compression on a rotary press with 9 mm round concave tooling at 8–18 kN produces tablet hardness of 60–100 N. Friability is controlled to ≤ 1.0% under USP <1216>, and content uniformity follows USP <905>. Capsule filling of the milled API blend is performed with a dosator or tamping-pin machine; fill weight variability is held below 3% RSD for a 100 mg total capsule mass.

Granule stability is sensitive to water activity. The granule is filled into hard gelatin capsules only after moisture equilibration below a_w 0.45 to prevent shell brittleness and softening. For moisture-sensitive packaging, aluminium foil blisters with PVC/PVDC or Aclar laminates are used; desiccant units maintain headspace relative humidity below 30%. The API oxidises more rapidly in the presence of iron and copper ions above 10 ppm in the granulation fluid; stainless-steel contact surfaces of 316L construction are preferred. Magnesium stearate is used at 0.5–1.0% w/w to reduce punch sticking, and compression tooling is maintained at 20–25°C with dry, oil-free air.

When Terminal Sterilization and pH Adjustment Accelerate Degradation in Injectable Formulations

For aqueous injectable products the free base is dissolved by addition of dilute hydrochloric acid to pH 3.0–4.5. The protonated diamino form increases aqueous solubility to more than 25 mg/mL, but the ionised state also increases susceptibility to oxidative discolouration. The compounding vessel is therefore sparged with nitrogen before and after dissolution, and the final vial headspace is flushed with nitrogen. Forced-degradation studies under air versus nitrogen have shown that oxygen exposure accelerates formation of sulfoxide and ring-opened products. Published data for this specific configuration are limited, so terminal sterilization should be justified by product-specific stress testing rather than by analogy to other benzothiazoles.

Sterile filtration through a 0.22 µm polyvinylidene fluoride or polyethersulfone membrane is suitable when terminal autoclaving is not feasible. If terminal sterilization is performed at 121°C for 15 min, the formulation pH should be held below 5.5 to reduce the degradation rate. Type I borosilicate glass vials with coated halogenobutyl stoppers are preferred to limit metal extractables. Particulate matter in the injectable is controlled according to USP <788>, and bacterial endotoxin is limited according to USP <85>. For a maximum daily parenteral dose of 10 mg/kg, an endotoxin limit of ≤ 0.5 EU/mg is typical; for higher doses the limit is calculated as 5 EU/kg per hour divided by the maximum dose. The bulk API for injectable use is released with a tighter endotoxin specification of ≤ 0.25 EU/mg.

Lyophilised injectable presentations are prepared by filling the acidified solution into glass vials and lyophilising at shelf temperatures from -40°C during freezing to 25°C during secondary drying. The final moisture specification is ≤ 1.0% w/w by Karl Fischer. Before administration the cake is reconstituted with water for injection to a concentration of 1–10 mg/mL. The freeze-dried form is less sensitive to oxygen than the ready-to-use solution, but the reconstituted solution should be used within 6 h when stored at 2–8°C. Incompatible additives include strong oxidising agents, peroxides, reducing sugars, and amine-based buffers that shift pH above 5.5 during processing.

Release Specifications and Supporting Methods for the S-(-) Free Base

Table 1 summarises the release parameters applied to the pharma grade API. The specifications are aligned with ICH Q6A for new drug substances and with current pharmacopoeial general chapters for the relevant dosage form. Each batch is tested before release; a certificate of analysis includes the actual values and the method reference.

Selection between the S-(-) free base and the racemic mixture is not only a chemical purity decision; it also affects process robustness and dosage form stability. Table 2 compares the S-(-) pharma grade free base with the racemic free base and technical-grade material across process-relevant attributes.

The S-(-) free base is also differentiated from the corresponding dihydrochloride salt. The salt is more freely soluble in water at neutral pH and may be used directly in aqueous injection, whereas the free base requires acidification with dilute hydrochloric acid. However, the free base has lower hygroscopicity and is often preferred in dry granulation or capsule blends where water uptake must be minimised. If the salt is used, assay correction for the counterion is required because the free base equivalent mass differs. The free base permits in situ salt selection but introduces a pH-dependent solubility step; therefore the choice between free base and salt should be fixed before process validation and supported by forced-degradation and dissolution data rather than by convenience of material handling.

Operational boundaries apply during dispensing and manufacturing. Exposure to ambient humidity above 60% RH for more than 8 h should be avoided once the inner liner is opened. The API should not be micronised under air for injectable drying if the resulting surface area increase accelerates oxidation; nitrogen-blanketed micronisation is preferred. Contact with copper, iron, or oxidising process aids should be excluded, and aqueous processing should be completed at pH below 5.5 unless product-specific stability data support a higher pH. These constraints are part of the material specification and should be evaluated in the drug product quality risk assessment before scale-up.